Evidence map›Paper›PMID 31463605›Full record

ReviewHandbook of experimental pharmacology2020

The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research.

Matthew L Banks

Open access · greenAbstract readReview
In one paragraph

Review in Handbook of experimental pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. A review of the kappa opioid receptor system in opioid use.Neuroscience and biobehavioral reviews · 2024
    Pooled it
  2. Trial
  3. A widespread internal brain state for fentanyl withdrawal.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Kappa opioid receptor control of motivated behavior revisited.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  7. Kappa Opioid Receptors Control a Stress-Sensitive Brain Circuit and Drive Cocaine Seeking.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  8. Article
  9. Dezocine and Addiction: Friend or Foe?Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. The role of miRNA-144-3p/Oprk1/KOR in nicotine dependence and nicotine withdrawal in male rats.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023
    Article
  15. Article
  16. Epigenetic Modulation of Opioid Receptors by Drugs of Abuse.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA. matthew.banks@vcuhealth.org.
Virginia Commonwealth University · US

Funding

Behavioral effects of NMDA antagonist/opioid agonist combinationsR01DA037287 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BANKS, MATTHEW L, NICHOLSON, KATHERINE L · 2014 to 2018
$2.0M
Treatment Development for Methamphetamine AbuseR01DA031718 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BANKS, MATTHEW L · 2012 to 2014
$1.1M
NIDA NIH HHS R01 DA031718NIDA NIH HHS R01 DA037287
6 · The paper itself

Abstract

Substance use disorders represent a global public health issue. This mental health disorder is hypothesized to result from neurobiological changes as a result of chronic drug exposure and clinically manifests as inappropriate behavioral allocation toward the procurement and use of the abused substance and away from other behaviors maintained by more adaptive nondrug reinforcers (e.g., social relationships, work). The dynorphin/kappa-opioid receptor (KOR) is one receptor system that has been altered following chronic exposure to drugs of abuse (e.g., cocaine, opioids, alcohol) in both laboratory animals and humans, implicating the dynorphin/KOR system in the expression, mechanisms, and treatment of substance use disorders. KOR antagonists have reduced drug self-administration in laboratory animals under certain experimental conditions, but not others. Recently, several human laboratory and clinical trials have evaluated the effectiveness of KOR antagonists as candidate pharmacotherapies for cocaine or tobacco use disorder to test hypotheses generated from preclinical studies. KOR antagonists failed to significantly alter drug use metrics in humans suggesting translational discordance between some preclinical drug self-administration studies and consistent with other preclinical drug self-administration studies that provide concurrent access to an alternative nondrug reinforcer (e.g., food). The implications of this translational discordance and future directions for examining the therapeutic potential of KOR agonists or antagonists as candidate substance use disorder pharmacotherapies are discussed.

Indexed as

AnimalsDynorphinsHumansReceptors, Opioid, kappaSubstance-Related DisordersDynorphinsReceptors, Opioid, kappaCocaineEthanolKappa opioid receptorMedication developmentNicotineOpioid

Identifiers

PMID31463605
PMCPMC7756963
OpenAlexW2971182958

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.